Hanx Biopharmaceuticals has dosed the first patient in a Phase 1 clinical trial of HX044 in Australia, an innovative bispecific antibody for advanced solid tumors.
HanX Biopharmaceuticals is planning an IPO in Hong Kong to fund clinical trials for its lead drug candidate, HX009, a bispecific antibody targeting PD-1 and CD47.
CD47-targeted therapies are emerging as a novel cancer immunotherapy approach, inhibiting the "don't eat me" signal that cancer cells use to evade immune surveillance.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.